Trefoil Factor 3, Cholinesterase and Homocysteine: Potential Predictors for Parkinson's Disease Dementia and Vascular Parkinsonism Dementia in Advanced Stage.
Trefoil Factor 3, Cholinesterase and Homocysteine: Potential Predictors for Parkinson's Disease Dementia and Vascular Parkinsonism Dementia in Advanced Stage.
复制标题
三叶因子 3、胆碱酯酶和同型半胱氨酸：帕金森病痴呆和晚期血管性帕金森痴呆的潜在预测因素
DOI：
10.14336/ad.2017.0416
复制
发表时间：
2018-03
影响因子：
7.4
通讯作者：
Wang Q
中科院分区：
文献类型：
--
作者：
Zou J;Chen Z;Liang C;Fu Y;Wei X;Lu J;Pan M;Guo Y;Liao X;Xie H;Wu D;Li M;Liang L;Wang P;Wang Q
三叶因子3（TFF 3）、胆碱酯酶活性（ChE活性）和同型半胱氨酸（Hcy）在神经退行性疾病（如帕金森病痴呆（PDD）和血管性帕金森综合征伴痴呆（VPD））的识别、学习和记忆调节中起关键作用。然而，它们是否可以作为可靠的预测因子来评估PDD和VPD的严重程度和进展仍然是未知的。方法：我们进行了一项横断面研究，包括92例PDD患者，82例VPD患者和80名健康对照。检测血清TFF 3、ChE活性和Hcy水平。采用多个量表评定PDD和VPD的严重程度。应用受试者工作特征（ROC）曲线绘制PDD和VPD患者与健康受试者相比的诊断准确性。结果：PDD和VPD患者血清TFF 3和ChE活性均低于健康对照组，而Hcy水平高于健康对照组。这些发现在男性患者中尤为突出。三种生物标志物在PDD和VPD亚组之间显示出基于性别的差异和PDRS（III）评分的分布。有趣的是，这些增加的血清同型半胱氨酸水平显着负相关，降低TFF 3/胆碱酯酶活性水平。TFF 3/ChE活性/Hcy水平与PDD/VPD严重程度（包括运动功能障碍、认知功能下降和情绪/胃肠道症状）显著相关。此外，TFF 3、ChE活性和Hcy的组合的ROC曲线显示了区分PDD和VPD患者与健康对照的潜在诊断价值。结论：TFF 3、ChE活性和Hcy水平可能是PDD和VPD的病理生理基础。随着寻找这些疾病的生物标志物或预测因子的竞赛加剧，更好地了解TFF 3，ChE活性和Hcy的作用可能会深入了解PDD和VPD的发病机制。
Trefoil factor 3 (TFF3), cholinesterase activity (ChE activity) and homocysteine (Hcy) play critical roles in modulating recognition, learning and memory in neurodegenerative diseases, such as Parkinson’s disease dementia (PDD) and vascular parkinsonism with dementia (VPD). However, whether they can be used as reliable predictors to evaluate the severity and progression of PDD and VPD remains largely unknown. Methods: We performed a cross-sectional study that included 92 patients with PDD, 82 patients with VPD and 80 healthy controls. Serum levels of TFF3, ChE activity and Hcy were measured. Several scales were used to rate the severity of PDD and VPD. Receivers operating characteristic (ROC) curves were applied to map the diagnostic accuracy of PDD and VPD patients compared to healthy subjects. Results: Compared with healthy subjects, the serum levels of TFF3 and ChE activity were lower, while Hcy was higher in the PDD and VPD patients. These findings were especially prominent in male patients. The three biomarkers displayed differences between PDD and VPD sub-groups based on genders and UPDRS (III) scores’ distribution. Interestingly, these increased serum Hcy levels were significantly and inversely correlated with decreased TFF3/ChE activity levels. There were significant correlations between TFF3/ChE activity/Hcy levels and PDD/VPD severities, including motor dysfunction, declining cognition and mood/gastrointestinal symptoms. Additionally, ROC curves for the combination of TFF3, ChE activity and Hcy showed potential diagnostic value in discriminating PDD and VPD patients from healthy controls. Conclusions: Our findings suggest that serum TFF3, ChE activity and Hcy levels may underlie the pathophysiological mechanisms of PDD and VPD. As the race to find biomarkers or predictors for these diseases intensifies, a better understanding of the roles of TFF3, ChE activity and Hcy may yield insights into the pathogenesis of PDD and VPD.